Turnstone Biologics Corp. (TSBX)

NASDAQ: TSBX · IEX Real-Time Price · USD
2.450
-0.060 (-2.39%)
At close: Jul 12, 2024, 4:00 PM
2.510
+0.060 (2.45%)
After-hours: Jul 12, 2024, 5:34 PM EDT
-2.39%
Market Cap 56.66M
Revenue (ttm) 19.31M
Net Income (ttm) -74.92M
Shares Out 23.13M
EPS (ttm) -9.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39,256
Open 2.540
Previous Close 2.510
Day's Range 2.330 - 2.600
52-Week Range 1.625 - 13.200
Beta n/a
Analysts Strong Buy
Price Target 19.00 (+675.51%)
Earnings Date Aug 30, 2024

About TSBX

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company’s lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of sol... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 21, 2023
Employees 82
Stock Exchange NASDAQ
Ticker Symbol TSBX
Full Company Profile

Financial Performance

In 2023, TSBX's revenue was $19.31 million, a decrease of -73.66% compared to the previous year's $73.30 million. Losses were -$55.24 million, 78.1% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TSBX stock is "Strong Buy." The 12-month stock price forecast is $19.0, which is an increase of 675.51% from the latest price.

Price Target
$19.0
(675.51% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to trea...

2 months ago - GlobeNewsWire

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to trea...

2 months ago - GlobeNewsWire

Turnstone Biologics Appoints William Waddill to its Board of Directors

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tr...

3 months ago - GlobeNewsWire

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors pre...

4 months ago - GlobeNewsWire

Turnstone Biologics to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tre...

5 months ago - GlobeNewsWire

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tre...

5 months ago - GlobeNewsWire

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.

8 months ago - GlobeNewsWire

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

– Promising preclinical data showcasing Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 – – Lead program, TIDAL-01, advancing and on track in two Phase 1 trials with in...

8 months ago - GlobeNewsWire

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Posters showcase Turnstone's novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.

9 months ago - GlobeNewsWire

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone's continued advancement of its Selected TIL therapies

9 months ago - GlobeNewsWire

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...

10 months ago - GlobeNewsWire

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: SCLXSGHTTNYA
10 months ago - Benzinga

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...

11 months ago - GlobeNewsWire

FMR LLC Acquires Significant Stake in Turnstone Biologics Corp

On July 25, 2023, FMR LLC (Trades, Portfolio), a renowned investment firm, made a significant move in the biotechnology sector by acquiring a substantial stake in Turnstone Biologics Corp ( TSBX , Fin...

1 year ago - GuruFocus

Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range

Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offe...

1 year ago - Market Watch

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure ...

1 year ago - GlobeNewsWire

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced ...

1 year ago - Market Watch